Advanced Filters
noise

transplant-rejection Clinical Trials

A listing of transplant-rejection medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 85 clinical trials
G Giles Santyr, PhD

HP 129Xe MRI for Evaluation of CLAD in Lung Transplant Recipients

To evaluate the feasibility of hyperpolarized 129Xe MRI in lung transplant recipients and assess structural and functional pulmonary changes using hyperpolarized 129Xe MRI

18 - 75 years of age Both Phase 2
C Carolin Steinack, MD

Noninvasive Early Detection of Lung Allograft Dysfunction After Lung Transplantation With Multiple Breath Washout Test

Chronic rejection, more commonly called bronchiolitis obliterans syndrome (BOS), is the leading cause of death beyond the first year post lung transplantation. The diagnosis of BOS is typically made by clinical, physiological, and radiographic parameters. Early detection would be desirable since it allows treatment modification to stop or delay the …

18 - 100 years of age Both Phase N/A
P Paul Kim, MD

Allograft Dysfunction in Heart Transplant

The investigators will evaluate for early evidence of cardiac allograft dysfunction by cardiac MRI and single cell sequencing to determine underlying molecular and macroscopic causes.

18 - 100 years of age Both Phase 4
K Karsten Midtvedt, MD, PhD

Home Based Monitoring of Kidney Transplants Utilizing Capillary Microsamples

Renal transplant recipients are followed as out patients at the transplant center for about 8 weeks after surgery. Between 1-2 weeks after surgery, 50 standard immunological patients will be randomized (1:1) to either follow standard of care (SOC) or having every second poli clinical visit without entering the hospital HBM; …

18 - 100 years of age Both Phase N/A
D Domingo Hernández, MD,PhD

Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING)

Background: Subclinical inflammation, including borderline lesions (BL), is very common (30-40%) after kidney transplantation (KT), even in low immunological risk patients, and can lead to interstitial fibrosis/tubular atrophy (IFTA) and worsening of renal function with graft loss. Few controlled studies have analyzed the therapeutic benefit of these BL on renal …

18 - 100 years of age Both Phase 4
A Alice KOENIG, MD

Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection

Background Long-term success of organ transplantation is limited by the inexorable loss of graft function due to rejection. Prevalent dogma defends that allograft rejection is exclusively mediated by the adaptive immune system: T cells are responsible for cellular rejections and B cells producing Donor Specific Antibodies (DSA) are responsible for …

18 - 100 years of age Both Phase N/A

Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation

Transplant results vary considerably from one organ to another. Lung transplantation has poorer long-term outcomes than other solid organ transplants, with a current median post-transplant survival of 6.0 years. Allograft rejection remains the leading cause of morbidity and mortality in all organ groups and is the leading cause of death, …

15 - 100 years of age Both Phase N/A
B Bertrand CHAUVEAU, Dr

Mass Spectrometry-based Proteomics in Microvascular Inflammation Diagnosis in Kidney Transplantation.

Microvascular inflammation, the hallmark histological criteria of antibody-mediated rejection in kidney transplantation, remains an issue in routine practice, due to a lack of reproducibility in its recognition by pathologists and an incomplete comprehension of its pathophysiology, leading to a poor treatment efficacy. The main objective of this study is to …

18 - 100 years of age Both Phase N/A
M Melissa Ramos

Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR

The purpose of this study is to determine if the combination of once-daily tacrolimus extended-release (EnvarsusXR) and Azathioprine is non inferior with respect to the composite outcome of acute rejection, graft and patient survival as compared to a combination of twice-daily immediate release tacrolimus and mycophenolate mofetil/mycophenolic acid.

18 - 85 years of age Both Phase 4
D Dana Levin, MPH

Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor

The purpose of this study is to find out if an investigational treatment will allow kidney transplant recipients to better accept their new kidney and stop immunosuppressive medicines. This study is for kidney transplant recipients who receive a kidney from a sibling donor. The investigational treatment is started after kidney …

18 - 100 years of age Both Phase 1/2

Rewrite in simple language using AI